R
Rana Abdelnabi
Researcher at Rega Institute for Medical Research
Publications - 76
Citations - 3643
Rana Abdelnabi is an academic researcher from Rega Institute for Medical Research. The author has contributed to research in topics: Virus & Biology. The author has an hindex of 16, co-authored 52 publications receiving 1409 citations. Previous affiliations of Rana Abdelnabi include Global Virus Network & University of Salerno.
Papers
More filters
Journal ArticleDOI
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
Matthew McCallum,Anna De Marco,Florian A. Lempp,M. Alejandra Tortorici,M. Alejandra Tortorici,Dora Pinto,Alexandra C. Walls,Martina Beltramello,Alexander Chen,Zhuoming Liu,Fabrizia Zatta,Samantha K Zepeda,Julia di Iulio,John E. Bowen,Martin Montiel-Ruiz,Jiayi Zhou,Laura E. Rosen,Siro Bianchi,Barbara Guarino,Chiara Silacci Fregni,Rana Abdelnabi,Shi Yan Caroline Foo,Paul W. Rothlauf,Louis Marie Bloyet,Fabio Benigni,Elisabetta Cameroni,Johan Neyts,Agostino Riva,Gyorgy Snell,Amalio Telenti,Sean P. J. Whelan,Herbert W. Virgin,Davide Corti,Matteo Samuele Pizzuto,David Veesler +34 more
TL;DR: In this article, 41 human monoclonal antibodies derived from memory B cells were used to identify the SARS-CoV-2 S N-terminal domain (NTD).
Journal ArticleDOI
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
M. Alejandra Tortorici,M. Alejandra Tortorici,Martina Beltramello,Florian A. Lempp,Dora Pinto,Ha V. Dang,Laura E. Rosen,Matthew McCallum,John E. Bowen,Andrea Minola,Stefano Jaconi,Fabrizia Zatta,Anna De Marco,Barbara Guarino,Siro Bianchi,Elvin J. Lauron,Heather Tucker,Jiayi Zhou,Alessia Peter,Colin Havenar-Daughton,Jason A. Wojcechowskyj,James Brett Case,Rita E. Chen,Hannah Kaiser,Martin Montiel-Ruiz,Marcel Meury,Nadine Czudnochowski,Roberto Spreafico,Josh Dillen,Cindy Ng,Nicole Sprugasci,Katja Culap,Fabio Benigni,Rana Abdelnabi,Shi Yan Caroline Foo,Michael A. Schmid,Elisabetta Cameroni,Agostino Riva,Arianna Gabrieli,Massimo Galli,Matteo Samuele Pizzuto,Johan Neyts,Michael S. Diamond,Herbert W. Virgin,Herbert W. Virgin,G. Snell,Davide Corti,Katja Fink,David Veesler +48 more
TL;DR: The isolation and characterization of two ultrapotent Sars-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-Cov-2 challenge and pave the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the emergence of viral escape mutants.
Journal ArticleDOI
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Tyler N. Starr,Nadine Czudnochowski,Zhuoming Liu,Fabrizia Zatta,Young-Jun Park,Amin Addetia,Dora Pinto,Martina Beltramello,Patrick Hernandez,Allison J. Greaney,Allison J. Greaney,Roberta Marzi,William G. Glass,Ivy Zhang,Ivy Zhang,Adam S. Dingens,John E. Bowen,M. Alejandra Tortorici,Alexandra C. Walls,Jason A. Wojcechowskyj,Anna De Marco,Laura E. Rosen,Jiayi Zhou,Martin Montiel-Ruiz,Hannah Kaiser,Josh Dillen,Heather Tucker,Jessica Bassi,Chiara Silacci-Fregni,Michael P. Housley,Julia di Iulio,Gloria Lombardo,Maria L. Agostini,Nicole Sprugasci,Katja Culap,Stefano Jaconi,Marcel Meury,Exequiel Dellota,Rana Abdelnabi,Shi-Yan Caroline Foo,Elisabetta Cameroni,Spencer Stumpf,Tristan I. Croll,Jay C. Nix,Colin Havenar-Daughton,Luca Piccoli,Fabio Benigni,Johan Neyts,Amalio Telenti,Florian A. Lempp,Matteo Samuele Pizzuto,John D. Chodera,Christy M. Hebner,Herbert W. Virgin,Herbert W. Virgin,Sean P. J. Whelan,David Veesler,Davide Corti,Jesse D. Bloom,Jesse D. Bloom,Jesse D. Bloom,Gyorgy Snell +61 more
TL;DR: In this paper, the authors comprehensively characterize escape, breadth and potency across a panel of SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD).
Journal ArticleDOI
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
TL;DR: The potential of favipiravir as a broad‐spectrum antiviral seems promising, but safety and potency issues should be overcome before this drug or similar molecules could be used to treat large patient groups.
Journal ArticleDOI
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity
Suzanne J.F. Kaptein,Sofie Jacobs,Lana Langendries,Laura Seldeslachts,Sebastiaan ter Horst,Laurens Liesenborghs,Bart Hens,Valentijn Vergote,Elisabeth Heylen,Karine Barthélémy,Elke Maas,Carolien De Keyzer,Lindsey Bervoets,Jasper Rymenants,Tina Van Buyten,Xin Zhang,Rana Abdelnabi,Juanita Pang,Rachel Williams,Hendrik Jan Thibaut,Kai Dallmeier,Robbert Boudewijns,Jens Wouters,Patrick Augustijns,Nick Verougstraete,Christopher Cawthorne,Judith Breuer,Caroline Solas,Birgit Weynand,Pieter Annaert,Isabel Spriet,Greetje Vande Velde,Johan Neyts,Johan Neyts,Joana Rocha-Pereira,Leen Delang +35 more
TL;DR: In vivo preclinical results with favipiravir indicate that antiviral efficacy against SARS-CoV-2 might only be achieved with a very high dose, whereas hydroxychloroquine, completely lacks antiviral activity, provides no scientific basis for its further use in COVID-19 patients and demonstrates that an antiviral drug at nontoxic doses exhibits a marked protective effect in a small animal model.